BlossomHill Therapeutics (NASDAQ:BLSM) Cut to Sell at Wall Street Zen

Posted by Stanley Muller on Oct 6th, 2026

Wall Street Zen lowered shares of BlossomHill Therapeutics (NASDAQ:BLSM – Free Report) from a hold rating to a sell rating in a research report released on Saturday morning,Wall Street Zen reports.

Several other research analysts have also recently issued reports on BLSM. Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price objective for the company. HC Wainwright restated a “buy” rating on shares of BlossomHill Therapeutics in a report on Wednesday, September 30th. Lifesci Capital began coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 target price on the stock. Finally, Guggenheim upped their target price on BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, BlossomHill Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Get Our Latest Stock Report on BLSM

BlossomHill Therapeutics Stock Performance

Shares of BLSM opened at $19.94 on Friday. The stock has a 50 day simple moving average of $19.89. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last released its earnings results on Friday, September 18th. The company reported ($8.75) EPS for the quarter, missing the consensus estimate of ($0.84) by ($7.91). As a group, research analysts forecast that BlossomHill Therapeutics will post -5.54 EPS for the current fiscal year.

Insider Buying and Selling at BlossomHill Therapeutics

In other news, Director Orbimed Advisors Llc acquired 625,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the purchase, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bihua Chen acquired 312,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the purchase, the director directly owned 3,614,034 shares in the company, valued at approximately $57,824,544. This trade represents a 9.47% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 1,573,900 shares of company stock valued at $25,181,900 over the last three months.

BlossomHill Therapeutics Company Profile

(Get Free Report)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.